123 related articles for article (PubMed ID: 33176482)
1. Synthesis and antiviral activity of lycorine derivatives.
Yang YJ; Liu JN; Pan XD
J Asian Nat Prod Res; 2020 Dec; 22(12):1188-1196. PubMed ID: 33176482
[TBL] [Abstract][Full Text] [Related]
2. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication.
Liu J; Yang Y; Xu Y; Ma C; Qin C; Zhang L
Virol J; 2011 Oct; 8():483. PubMed ID: 22029605
[TBL] [Abstract][Full Text] [Related]
3. Lycorine Derivative LY-55 Inhibits EV71 and CVA16 Replication Through Downregulating Autophagy.
Wang H; Guo T; Yang Y; Yu L; Pan X; Li Y
Front Cell Infect Microbiol; 2019; 9():277. PubMed ID: 31448243
[TBL] [Abstract][Full Text] [Related]
4. A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C Virus.
Guo Y; Wang Y; Cao L; Wang P; Qing J; Zheng Q; Shang L; Yin Z; Sun Y
Antimicrob Agents Chemother; 2016 Feb; 60(2):913-24. PubMed ID: 26596952
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.
Caine EA; Fuchs J; Das SC; Partidos CD; Osorio JE
Viruses; 2015 Nov; 7(11):5919-32. PubMed ID: 26593938
[TBL] [Abstract][Full Text] [Related]
6. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
7. Antiviral activity of Paulownia tomentosa against enterovirus 71 of hand, foot, and mouth disease.
Ji P; Chen C; Hu Y; Zhan Z; Pan W; Li R; Li E; Ge HM; Yang G
Biol Pharm Bull; 2015; 38(1):1-6. PubMed ID: 25744451
[TBL] [Abstract][Full Text] [Related]
8. Estimation of the basic reproduction number of enterovirus 71 and coxsackievirus A16 in hand, foot, and mouth disease outbreaks.
Ma E; Fung C; Yip SH; Wong C; Chuang SK; Tsang T
Pediatr Infect Dis J; 2011 Aug; 30(8):675-9. PubMed ID: 21326133
[TBL] [Abstract][Full Text] [Related]
9. EV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccines.
Klein MH
Expert Rev Vaccines; 2015 Mar; 14(3):337-40. PubMed ID: 25536888
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
11. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
Cai Y; Ku Z; Liu Q; Leng Q; Huang Z
Vaccine; 2014 May; 32(21):2406-12. PubMed ID: 24657161
[TBL] [Abstract][Full Text] [Related]
12.
Meng T; Jia Q; Wong SM; Chua KB
J Virol; 2019 Sep; 93(17):. PubMed ID: 31167919
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice.
Huo C; Yang J; Lei L; Qiao L; Xin J; Pan Z
Vaccine; 2017 Dec; 35(52):7322-7330. PubMed ID: 29129453
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of human enterovirus 71 and coxsackie virus A16 and hand, foot, and mouth disease.
Kadurugamuwa JL; Shaheen E
Am J Infect Control; 2011 Nov; 39(9):788-9. PubMed ID: 21565426
[TBL] [Abstract][Full Text] [Related]
15. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.
Yang L; Liu Y; Li S; Zhao H; Lin Q; Yu H; Huang X; Zheng Q; Cheng T; Xia N
Vaccine; 2016 Nov; 34(48):5938-5945. PubMed ID: 27771182
[TBL] [Abstract][Full Text] [Related]
16. Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
Yang Y; Guan F; Bai L; Zhang L; Liu J; Pan X; Zhang L
Bioorg Med Chem Lett; 2015 Sep; 25(17):3526-8. PubMed ID: 26189894
[TBL] [Abstract][Full Text] [Related]
17. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
[TBL] [Abstract][Full Text] [Related]
18. Anti-dengue-virus activity and structure-activity relationship studies of lycorine derivatives.
Wang P; Li LF; Wang QY; Shang LQ; Shi PY; Yin Z
ChemMedChem; 2014 Jul; 9(7):1522-33. PubMed ID: 24574246
[TBL] [Abstract][Full Text] [Related]
19. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71.
Zhang C; Yang Y; Chi Y; Yin J; Yan L; Ku Z; Liu Q; Huang Z; Zhou D
Vaccine; 2015 Sep; 33(39):5087-94. PubMed ID: 26296491
[TBL] [Abstract][Full Text] [Related]
20. Differential interferon pathway gene expression patterns in Rhabdomyosarcoma cells during Enterovirus 71 or Coxsackievirus A16 infection.
Zhang W; Zhang L; Wu Z; Tien P
Biochem Biophys Res Commun; 2014 May; 447(3):550-5. PubMed ID: 24735544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
